omacetaxine + imatinib

**Omacetaxine + imatinib** is an experimental combination therapy investigated primarily for the treatment of chronic myeloid leukemia (CML), especially in advanced phases or cases resistant to tyrosine kinase inhibitors (TKIs). Omacetaxine mepesuccinate, a semisynthetic derivative of homoharringtonine, is a protein translation inhibitor that downregulates key oncoproteins including BCR-ABL. Imatinib is a small molecule tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, the major driver oncogene in CML. The combination aims to provide synergistic inhibition of leukemic cells by attacking the disease via distinct mechanisms, showing preclinical and some clinical efficacy in TKI-resistant and advanced CML, with most studies conducted in academic and clinical trial settings.